-
公开(公告)号：US20230248683A1
公开(公告)日：2023-08-10
申请号：US18300924
申请日：2023-04-14
申请人： Kura Oncology, Inc.
发明人： Francis Burrows , Yi Liu
IPC分类号： A61K31/223 , A61P35/00 , A61K33/243 , A61K31/045 , A61K31/365 , A61K31/4155 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K39/395 , A61K45/06
CPC分类号： A61K31/223 , A61P35/00 , A61K33/243 , A61K31/045 , A61K31/365 , A61K31/4155 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K39/3955 , A61K45/06
摘要： The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
-
公开(公告)号：US10077271B2
公开(公告)日：2018-09-18
申请号：US15829604
申请日：2017-12-01
发明人： Jolanta Grembecka , Tomasz Cierpicki , Dmitry Borkin , Jonathan Pollock , Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu , Szymon Klossowski
IPC分类号： C07D487/04 , C07D473/34 , C07D495/04 , C07D491/048 , C07D513/04 , C07D519/00 , C07D498/04
CPC分类号： C07D487/04 , C07D473/34 , C07D491/048 , C07D495/04 , C07D498/04 , C07D513/04 , C07D519/00
摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
-
公开(公告)号：USRE49687E1
公开(公告)日：2023-10-10
申请号：US17165794
申请日：2021-02-02
发明人： Jolanta Grembecka , Tomasz Cierpicki , Dmitry Borkin , Jonathan Pollock , Hongzhi Miao , Duxin Sun , Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu
IPC分类号： C07D495/04 , C07D519/00 , C07F9/53 , C07F9/6558
CPC分类号： C07D495/04 , C07D519/00 , C07F9/5325 , C07F9/65583
摘要： The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
-
公开(公告)号：US10588907B2
公开(公告)日：2020-03-17
申请号：US15578837
申请日：2016-06-03
发明人： Jolanta Grembecka , Tomasz Cierpicki , Dmitry Borkin , Jonathan Pollock , Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu
IPC分类号： C07D471/04 , C07D401/14 , A61K31/519 , A61P35/02 , A61P3/10 , A61K31/5377 , A61K31/541
摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
-
公开(公告)号：US10174041B2
公开(公告)日：2019-01-08
申请号：US16014996
申请日：2018-06-21
发明人： Jolanta Grembecka , Tomasz Cierpicki , Dmitry Borkin , Jonathan Pollock , Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu , Szymon Klossowski
IPC分类号： C07D487/04 , C07D519/00 , C07D513/04 , C07D498/04 , C07D495/04 , C07D491/048 , C07D473/34
摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
-
公开(公告)号：US11672774B2
公开(公告)日：2023-06-13
申请号：US17488194
申请日：2021-09-28
申请人： Kura Oncology, Inc.
发明人： Francis Burrows , Yi Liu
IPC分类号： A61K31/223 , A61P35/00 , A61K33/243 , A61K31/045 , A61K31/365 , A61K31/4155 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K39/395 , A61K45/06
CPC分类号： A61K31/223 , A61K31/045 , A61K31/365 , A61K31/4155 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/519 , A61K31/55 , A61K31/5513 , A61K33/243 , A61K39/3955 , A61K45/06 , A61P35/00
摘要： The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
-
公开(公告)号：US11542248B2
公开(公告)日：2023-01-03
申请号：US16619423
申请日：2018-06-07
发明人： Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu , Jolanta Grembecka , Tomasz Cierpicki , Dmitry Borkin , Jonathan Pollock
IPC分类号： C07D401/14 , A61P35/00 , C07D207/32 , C07D413/14 , C07D417/14 , C07K14/47 , A61K9/00 , A61K38/00
摘要： The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
-
公开(公告)号：US20190292194A1
公开(公告)日：2019-09-26
申请号：US16370718
申请日：2019-03-29
申请人： Kura Oncology, Inc.
发明人： Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu
IPC分类号： C07D487/04 , A61K31/4439 , C07B59/00 , C07D519/00 , A61K45/06 , A61K9/00 , A61P35/00 , A61K31/4745 , A61K31/513 , A61K31/5377 , A61K31/5517 , C07D471/04
摘要： The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
-
公开(公告)号：US20180237444A1
公开(公告)日：2018-08-23
申请号：US15896929
申请日：2018-02-14
申请人： Kura Oncology, Inc.
发明人： Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu
IPC分类号： C07D487/04 , C07B59/00 , C07D519/00 , C07D471/04
CPC分类号： C07D487/04 , A61K9/0053 , A61K31/4439 , A61K31/4745 , A61K31/513 , A61K31/5377 , A61K31/5517 , A61K45/06 , A61P35/00 , C07B59/002 , C07B2200/05 , C07D471/04 , C07D519/00
摘要： The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
-
公开(公告)号：US09951078B2
公开(公告)日：2018-04-24
申请号：US15439719
申请日：2017-02-22
申请人： KURA ONCOLOGY, INC.
发明人： Liansheng Li , Tao Wu , Jun Feng , Pingda Ren , Yi Liu
IPC分类号： C07D487/04 , A61K31/4439 , A61K31/513 , C07D471/04 , C07D519/00 , C07B59/00
CPC分类号： C07D487/04 , A61K9/0053 , A61K31/4439 , A61K31/4745 , A61K31/513 , A61K31/5377 , A61K31/5517 , A61K45/06 , A61P35/00 , C07B59/002 , C07B2200/05 , C07D471/04 , C07D519/00
摘要： The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.043 秒)
